Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBIT (2019 - 2025)

Pulmonx (LUNG) has disclosed EBIT for 7 consecutive years, with -$14.4 million as the latest value for Q3 2025.

  • Quarterly EBIT fell 1.87% to -$14.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$57.2 million through Sep 2025, up 1.77% year-over-year, with the annual reading at -$57.7 million for FY2024, 6.83% up from the prior year.
  • EBIT for Q3 2025 was -$14.4 million at Pulmonx, up from -$14.8 million in the prior quarter.
  • The five-year high for EBIT was -$9.8 million in Q3 2021, with the low at -$16.4 million in Q2 2023.
  • Average EBIT over 5 years is -$14.2 million, with a median of -$14.4 million recorded in 2022.
  • The sharpest move saw EBIT tumbled 104.69% in 2021, then rose 11.37% in 2024.
  • Over 5 years, EBIT stood at -$12.4 million in 2021, then fell by 18.28% to -$14.6 million in 2022, then rose by 4.84% to -$13.9 million in 2023, then increased by 3.61% to -$13.4 million in 2024, then decreased by 7.27% to -$14.4 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$14.4 million, -$14.8 million, and -$14.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.